(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 41.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Geron's revenue in 2025 is $164,447,000.On average, 5 Wall Street analysts forecast GERN's revenue for 2025 to be $129,285,227,604, with the lowest GERN revenue forecast at $127,131,281,966, and the highest GERN revenue forecast at $131,878,128,989. On average, 5 Wall Street analysts forecast GERN's revenue for 2026 to be $198,466,694,864, with the lowest GERN revenue forecast at $169,961,368,076, and the highest GERN revenue forecast at $219,733,079,941.
In 2027, GERN is forecast to generate $305,961,087,357 in revenue, with the lowest revenue forecast at $226,846,970,305 and the highest revenue forecast at $373,826,963,412.